Belyntic

Description

Belyntic develops T-Fender vaccines that use self-adjuvant, self-aggregating synthetic long peptides, combined with AI-based prediction, to induce pathogen-specific T cells for therapeutic and prophylactic protection against viral and bacterial reactivation.

Belyntic is located in the Berlin ecosystem.

Related

• MinervaXMinervaX is developing a prophylactic Group B Streptococcal (GBS) vaccine, AlpN GBS, that works as a clinical-stage immunization product…
• CytuvaxCytuvax develops cancer immunotherapy and vaccines for viral and bacterial pathogens, using depot-attached cytokines as immune-stimulating…
• EnzyTagEnzyTag develops peptiligase-based synthetic routes for manufacturing peptide new chemical entities, small proteins, and peptide…
• OsivaxOsivax develops oligoDOM self-assembling nanoparticle vaccines that activate T-cell and B-cell immunity for broader protection against…
• CimCureCimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy…
• Nia HealthNia Health develops indication-specific medical software platforms that deliver personalized digital therapeutics combining clinical…
• AAsgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…
• Bavarian NordicBavarian Nordic researches, develops, and manufactures life-saving vaccines, maintains product and pipeline materials, and operates process…
• CCeraVxCeraVx develops ceramic CeraMaps microneedle patches for intradermal delivery of vaccines and medicines, using biocompatible, inert…